Centers for Disease Control and Prevention - ERA

Description

Respiratory syncytial virus (RSV) is the leading viral cause of lower respiratory tract infection including bronchiolitis and pneumonia in infants and children worldwide. The annual rate of RSV hospitalizations for children less than 2 years of age in the US is 5.2 per 1,000, but substantially higher among Native Americans. There are currently approximately 40 vaccines or antibody products in development designed to prevent RSV infections. With potential licensure of these products on the horizon, it will be important to establish baseline estimates of the burden of RSV infections in high-risk populations, like Native Americans, and to maintain surveillance post-licensure in order to evaluate impact. Native Americans are also at higher risk for severe respiratory infections associated with human metapneumovirus (HMPV) and other viruses, which will also be monitored through this system.

Who can apply

• State governments
• County governments
• City or township governments
• Special district governments
• Independent school districts
• Public and State controlled institutions of higher education
• Native American tribal governments (Federally recognized)
• Public housing authorities / Indian housing authorities
• Native American tribal organizations (other than Federally recognized)
• Nonprofits with 501(c)(3) status (other than higher education)
• Nonprofits without 501(c)(3) status (other than higher education)
• Private institutions of higher education
• Others

Contact

Amy Yang<br/>vdz9@cdc.gov
vdz9@cdc.gov